Company Description
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
It operates through two segments: Clinical Services and Enabling Services.
The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process.
The company offers delivery models that include full service, functional service provider, and hybrid service structures.
It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services.
The company serves pharmaceutical, biotechnology, and medical device organizations.
Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
| Country | United States |
| IPO Date | Jun 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15,500 |
| CEO | Jill McConnell |
Contact Details
Address: 8 Moore Drive Durham, North Carolina United States | |
| Website | https://www.fortrea.com |
Stock Details
| Ticker Symbol | FTRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001965040 |
| CUSIP Number | 34965K107 |
| ISIN Number | US34965K1079 |
| Employer ID | 92-2796441 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Pike | Chief Executive Officer & Chairman |
| Jill McConnell | Chief Financial Officer |
| Mark A. Morais | Chief Operating Officer & President of Clinical Services |
| Dr. John J. Doyle M.D. | President of Consulting |
| Hima B. Inguva | Head of Investor Relations & Corporate Development |
| Robert Parks | Chief Accounting Officer |
| Stillman Hanson | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 4 | Filing |
| Aug 26, 2024 | 8-K/A | [Amend] Current Report |
| Aug 21, 2024 | 3 | Filing |
| Aug 20, 2024 | 4 | Filing |
| Aug 20, 2024 | 4 | Filing |
| Aug 20, 2024 | 4 | Filing |